<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00291473</url>
  </required_header>
  <id_info>
    <org_study_id>LMT2004-011</org_study_id>
    <nct_id>NCT00291473</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers</brief_title>
  <official_title>Safety and Immunogenicity of Cholesterol-Bearing Hydrophobized Pullulan HER2 Protein 146 (CHP-HER2) and NY-ESO-1 Protein (CHP-NY-ESO-1) in Combination With OK-432 in HER2- and/or NY-ESO-1-Expressing Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig Institute for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig Institute for Cancer Research</source>
  <brief_summary>
    <textblock>
      Mixed cancer vaccines, CHP-HER2 protein and CHP-NY-ESO-1 protein, are to be studied to&#xD;
      evaluate the safety and immune responses in patients who are positive either or both&#xD;
      antigens. Nine patients will be enrolled, who are refractory to standard therapies for cancer&#xD;
      or at high risk to relapse. CHP-HER2 and CHP-NY-ESO-1 are subcutaneously given on bimonthly&#xD;
      basis, together with OK-432(Picibanil) as an immunoadjuvant. Six doses will be given.&#xD;
      Toxicity profiles will be monitored, and antigen specific humoral anad T cell responses will&#xD;
      be described.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse events</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>immune responses including HER2 and NY-ESO-1 specific IgG and T cells</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Stomach Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHP-HER2, CHP-NY-ESO-1</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological confirmation of cancer.&#xD;
&#xD;
          2. HER2 expression in tumor cells scored as 1+ or more which should be confirmed by IHC&#xD;
             using at least two antibodies (archived issue; see Appendix 1 and Reference 1 for&#xD;
             methodology).&#xD;
&#xD;
             or NY-ESO-1 expression by reverse transcriptase and polymerase chain reaction (RT-PCR)&#xD;
             analysis (Appendix 2), preferably, or immunohistochemistry&#xD;
&#xD;
          3. Patients must&#xD;
&#xD;
               1. are at high risk of recurrence, more than 25% of probability, after complete&#xD;
                  resection or even after post-operative adjuvant treatment, and effective adjuvant&#xD;
                  therapy is not available or refused; or&#xD;
&#xD;
               2. have metastatic disease, and treatment has failed, or in the situation where&#xD;
                  effective therapy is not available, or has been refused.&#xD;
&#xD;
          4. Complete recovery from surgery (at least 4 weeks).&#xD;
&#xD;
          5. Laboratory values within the following limits:&#xD;
&#xD;
             Hemoglobin 9.0 g/dL or more, or 10.0 g/dL or more if &lt;50 kg Neutrophil count &gt;1.5 x&#xD;
             109/L Lymphocyte count &gt;0.5 x 109/L Platelet count &gt;100 x 109/L Serum creatinine ≤ 1.8&#xD;
             mg/dL Serum bilirubin ≤ 2 mg/dL&#xD;
&#xD;
          6. Performance status &gt; 70 (Karnofsky Scale) and life expectancy &gt;3 months.&#xD;
&#xD;
          7. Age 18 years or more.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant heart disease (NYHA Class III or IV).&#xD;
&#xD;
          2. Cardiac dysfunction; less than 50% of ejection fraction by echocardiogram.&#xD;
&#xD;
          3. Immunodeficiency disease.&#xD;
&#xD;
          4. Other serious illnesses, eg, serious infections requiring antibiotics, bleeding&#xD;
             disorders.&#xD;
&#xD;
          5. Previous bone marrow or stem cell transplant.&#xD;
&#xD;
          6. Metastatic disease to the central nervous system, unless treated and stable.&#xD;
&#xD;
          7. known HIV antibody positivity.&#xD;
&#xD;
          8. Anaphylactic reaction to previous vaccination.&#xD;
&#xD;
          9. Hypersensitivity to penicillin&#xD;
&#xD;
         10. Chemotherapy, any type of radiation therapy, or immunotherapy within 4 weeks before&#xD;
             study entry (6 weeks for nitrosoureas).&#xD;
&#xD;
         11. Concomitant treatment with steroids. Topical or inhalational steroids are permitted.&#xD;
&#xD;
         12. Participation in any other clinical trial involving another investigational agent&#xD;
             within 4 weeks prior to enrollment.&#xD;
&#xD;
         13. Pregnancy or nursing .&#xD;
&#xD;
         14. Refusal, by women of childbearing potential, to use medically acceptable means of&#xD;
             contraception.&#xD;
&#xD;
         15. Mental impairment that may compromise the ability to give informed consent.&#xD;
&#xD;
         16. Lack of availability for immunological and clinical follow-up assessment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroshi Shiku, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mie University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>February 10, 2006</study_first_submitted>
  <study_first_submitted_qc>February 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2006</study_first_posted>
  <last_update_submitted>March 2, 2009</last_update_submitted>
  <last_update_submitted_qc>March 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

